{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:36Z","timestamp":1793431956266,"version":"4.5.0"},"reference-count":16,"publisher":"Bentham Science Publishers Ltd.","issue":"2","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Osimertinib is a third-generation Tyrosine Kinase inhibitor, mainly used\nin non-small cell lung cancer with EGFR mutation. Its efficacy and safety have been confirmed by\nclinical practice. Toxic epidermolysis necrotizing disease (TEN) is a severe drug eruption that is\nrare in clinics and has a high mortality rate. Toxic epidermal necrotic drug rash caused by\nOsimeritinib is even rarer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>investigate the rare side effects of Osimertinib through a case of toxic Epidermal\nnecrosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>A 63-year-old female patient was diagnosed with lung adenocarcinoma with\nbrain metastases, and genetic testing revealed an EGFR21 exon mutation. The disease progressed\n24 days after the administration of gefitinib, then the patient switched to Osimertinib (80 mg QD)\nand, resulting in keratitis and secondary systemic toxic epidermolysis necrotizing disease (TEN).\nFinally, the patient died.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Although the clinical use of osimertinib is becoming widespread, the side effects may\nnot be fully understood. Clinicians should pay more attention to the occurrence of the side reaction\nand deal with it in time.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886318666230529123200","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:42:39Z","timestamp":1685511759000},"page":"309-312","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic\nDrug Eruption- A Case Report and Literature Review"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-360X","authenticated-orcid":true,"given":"Yunhua","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Oncology, Yi Ling Hospital of Yichang, Hubei Province 443002,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology,\nThe Second People's Hospital of Yichang, Hubei Province 443001,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yi Ling Hospital of Yichang, Hubei Province 443002,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yi Ling Hospital of Yichang, Hubei Province 443002,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"Mok T.S.","year":"2017","unstructured":"Mok T.S.; Wu Y.L.; Ahn M.J.; Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017,376(7),629-640","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"Soria J.C.","year":"2018","unstructured":"Soria J.C.; Ohe Y.; Vansteenkiste J.; Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018,378(2),113-125","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e21826","DOI":"10.1097\/MD.0000000000021826","volume":"99","author":"Liu J.","year":"2020","unstructured":"Liu J.; Li X.; Shao Y.; Guo X.; He J.; The efficacy and safety of osimertinib in treating nonsmall cell lung cancer. Medicine 2020,99(34),e21826","journal-title":"Medicine"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","volume":"136","author":"Hsu D.Y.","year":"2016","unstructured":"Hsu D.Y.; Brieva J.; Silverberg N.B.; Silverberg J.I.; Morbidity and mortality of Stevens-Johnson syndrome and toxic: Epidermal necrolysis in United States adults. J Invest Dermatol 2016,136(7),1387-1397","journal-title":"J Invest Dermatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"Lerch M.","year":"2018","unstructured":"Lerch M.; Mainetti C.; Beretta-Piccoli B.T.; Harr T.; Current perspectives on Stevens-Johnson syndrome and toxic epidermal necolysis. Clin Rev Allergy Immunol 2018,54(1),147-176","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"Lerch M.","year":"2018","unstructured":"Lerch M.; Mainetti C.; Terziroli Beretta-Piccoli B.; Harr T.; Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 2018,54(1),147-176","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","volume":"114","author":"Nassif A.","year":"2004","unstructured":"Nassif A.; Bensussan A.; Boumsell L.; Toxic epidermal necrolysis: Effector cells are drug-specific cyto-toxic T cells. J Allergy Clin Immunol 2004,114(5),1209-1215","journal-title":"J Allergy Clin Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.bjps.2016.04.016","volume":"69","author":"Wolkenstein P.","year":"2016","unstructured":"Wolkenstein P.; Wilson Y.T.; Toxic epidermal necrolysis: The past, the guidelines and challenges for the future. J Plast Reconstr Aesthet Surg 2016,69(6),733-735","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"Chung W-H.","year":"2004","unstructured":"Chung W-H.; Hung S-I.; Hong H-S.; A marker for Stevens\u2013Johnson syndrome. Nature [J].2004,428(6982),486","journal-title":"Nature"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","volume":"ll","author":"Hung S.I.","year":"2010","unstructured":"Hung S.I.; Chung W.H.; Liu Z.; Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Phamacogenomics 2010,ll(3),349-356","journal-title":"Phamacogenomics"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"Hung S.I.","year":"2005","unstructured":"Hung S.I.; Chung W.H.; Liou L.B.; HLA-B*580l allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 2005,102(11),4134-4139","journal-title":"Proc Natl Acad Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/jdv.13725","volume":"30","author":"Enk A.H.","year":"2016","unstructured":"Enk A.H.; Hadaschik E.N.; Eming R.; European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Eur Acad Dermatol Venereol 2016,30(10),1657-1669","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-5-39","volume":"5","author":"Harr T.","year":"2010","unstructured":"Harr T.; French L.E.; Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010,5(1),39","journal-title":"Orphanet J Rare Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2147\/DDDT.S168248","volume":"12","author":"Wang J.","year":"2018","unstructured":"Wang J.; Cheng X.; Lu Y.; Zhou B.; A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des Devel Ther 2018,12,2163-2167","journal-title":"Drug Des Devel Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/medicina56080403","volume":"56","author":"Sato I.","year":"2020","unstructured":"Sato I.; Mizuno H.; Kataoka N.; Osimertinib-associated toxic epidermal necrolysis in a lung cancer patient harboring an EGFR Mutation-A case report and a review of the literature. Medicina 2020,56(8),403","journal-title":"Medicina"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"Sassolas B.","year":"2010","unstructured":"Sassolas B.; Haddad C.; Mockenhaupt M.; ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010,88(1),60-68","journal-title":"Clin Pharmacol Ther"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886318666230529123200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217411\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886318666230529123200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:21:26Z","timestamp":1702470086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217411\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886318666230529123200","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}